Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

03:30 EDT 11 Jun 2019 | Pharmaceutical Business Review

Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ complex to treat cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine supposed

The post Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal appeared first on Pharmaceutical Business review.

Original Article: Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

More From BioPortfolio on "Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal"